Switch theme
Sign up to access all valuation multiples
Heartseed Inc is engaged in developing and commercializing iPS cell-derived cardiomyocyte replacement therapy for advanced heart failure.
2015
n/a
LTM Revenue n/a
LTM EBITDA n/a
$287M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Heartseed has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Heartseed achieved revenue of $5.8M and an EBITDA of -$5.2M.
Heartseed expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Heartseed valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $2.3M | $5.8M | XXX | XXX | XXX |
| Gross Profit | $3.3M | $2.3M | XXX | XXX | XXX |
| Gross Margin | 145% | 39% | XXX | XXX | XXX |
| EBITDA | -$9.6M | -$5.2M | XXX | XXX | XXX |
| EBITDA Margin | -420% | -89% | XXX | XXX | XXX |
| Net Profit | -$9.4M | -$9.8M | XXX | XXX | XXX |
| Net Margin | -410% | -169% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Heartseed's stock price is JPY 2171 (or $14).
Heartseed has current market cap of JPY 48.5B (or $322M), and EV of JPY 43.2B (or $287M).
See Heartseed trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $287M | $322M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Heartseed has market cap of $322M and EV of $287M.
Heartseed's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Heartseed's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Heartseed and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $287M | XXX | XXX | XXX |
| EV/Revenue | 49.5x | XXX | XXX | XXX |
| EV/EBITDA | -55.7x | XXX | XXX | XXX |
| P/E | -59.7x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -30.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpHeartseed's NTM/LTM revenue growth is n/a
Heartseed's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Heartseed's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Heartseed's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Heartseed and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 153% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -89% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -46% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 219% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Lineage Cell Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Arovella Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Aroa Biosurgery | XXX | XXX | XXX | XXX | XXX | XXX |
| Cynata Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Mesoblast | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Heartseed acquired XXX companies to date.
Last acquisition by Heartseed was XXXXXXXX, XXXXX XXXXX XXXXXX . Heartseed acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Heartseed founded? | Heartseed was founded in 2015. |
| Where is Heartseed headquartered? | Heartseed is headquartered in Japan. |
| Is Heartseed publicy listed? | Yes, Heartseed is a public company listed on TKS. |
| What is the stock symbol of Heartseed? | Heartseed trades under 219A ticker. |
| When did Heartseed go public? | Heartseed went public in 2024. |
| Who are competitors of Heartseed? | Similar companies to Heartseed include e.g. Lineage Cell Therapeutics, Arovella Therapeutics, Aroa Biosurgery, Cynata Therapeutics. |
| What is the current market cap of Heartseed? | Heartseed's current market cap is $322M |
| What is the current revenue growth of Heartseed? | Heartseed revenue growth between 2023 and 2024 was 153%. |
| Is Heartseed profitable? | Yes, Heartseed is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
